Jane Kendrew

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge, Donald Ogilvie, Michael Dukes et al. · PubMed · 2002 · 802 citations

Oral Administration, Pharmacotherapy, Tumor Biology +18

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin et al. · Cancer Research · 2005 · 706 citations · Full text

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains:  Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

Laurent Hennequin, Elaine S. E. Stokes, Andrew P. Thomas et al. · Journal of Medicinal Chemistry · 2002 · 308 citations · Full text

Combinatorial Chemistry, Tyrosine Kinase, Orally Active +16

Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors

Laurent Hennequin, Andrew P. Thomas, Craig Johnstone et al. · Journal of Medicinal Chemistry · 1999 · 235 citations · Full text

Medicinal Chemistry, Drug Target, Biochemistry +15

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Stephen R. Wedge, DJ Ogilvie, Michael Dukes et al. · PubMed · 2000 · 194 citations

Chemoprevention Strategy, Immunology, Pathology +18